Phospholipase signaling represents a critical pathway in neurodegeneration, involving phospholipase A2 (PLA2), phospholipase C (PLC), and phospholipase D (PLD). These enzymes regulate the arachidonic acid cascade, generating inflammatory lipid mediators that contribute to neuroinflammation in corticobasal syndrome (CBS) and progressive supranuclear palsy (PSP).
PLA2 hydrolyzes the sn-2 position of phospholipids, releasing arachidonic acid (AA) and lysophospholipids. In CBS/PSP, PLA2 activity is elevated 1.
Isoforms:
PLC hydrolyzes phosphatidylinositol 4,5-bisphosphate (PIP2) to generate inositol trisphosphate (IP3) and diacylglycerol (DAG) 2.
Isoforms:
AA metabolism produces inflammatory mediators:
PLA2 inhibitor development challenges:
PLC-targeted approaches:
Combination strategies:
PLD generates phosphatidic acid (PA) and choline, participating in:
PLD isoforms in the brain:
Therapeutic potential:
Phospholipases affect lipid rafts, membrane microdomains crucial for:
In CBS/PSP:
Multiple studies have demonstrated elevated phospholipase A2 activity in PSP brain tissue, particularly in regions with significant tau pathology[7]:
Recent proteomic and metabolomic studies have identified distinct lipid alterations in PSP[8]:
| Lipid Class | Change in PSP | Brain Region |
|---|---|---|
| Phosphatidylserine | Increased | Basal ganglia |
| Phosphatidylethanolamine | Decreased | Frontal cortex |
| Sphingomyelin | Increased | Substantia nigra |
| Ceramide | Increased | Brainstem |
| Cardiolipin | Decreased | Midbrain |
These alterations reflect:
The neuroinflammatory response in PSP involves bidirectional communication between PLA2 and cytokines[9]:
Phospholipase C signaling is altered in PSP, contributing to calcium dysregulation and excitotoxicity:
PLCβ isoforms: PLCβ1 and PLCβ4 show altered expression in PSP basal ganglia:
Second messenger consequences:
| Messenger | Change in PSP | Downstream Effect |
|---|---|---|
| IP3 | Increased | Altered calcium release |
| DAG | Elevated | PKC activation anomalies |
| Ca²⁺ | Dysregulated | Excitotoxicity |
Therapeutic targeting of PLC pathways:
Phospholipase D connections to tau pathology in PSP:
PLD therapeutic approaches in PSP:
| Agent | Target | Status | Evidence |
|---|---|---|---|
| VULM-1457 | PLD1/2 dual | Preclinical | Reduces tau pathology in PSP models |
| FIPI | PLD1/2 | Preclinical | Decreases tau phosphorylation |
| Alisporivir | Cyclophilin D-PLD | Preclinical | Restores mitophagy |
The predominance of 4R tau in PSP provides unique phospholipase interactions:
4R tau-PLA2 interaction: 4R tau isoforms show higher affinity for neuronal membranes, enhancing PLA2 accessibility
Phospholipase isoform expression in 4R-tauopathies:
| PLA2 isoform | PSP | CBD | AD |
|---|---|---|---|
| cPLA2 (IVA) | +++ | ++ | ++ |
| iPLA2 (VIA) | ++ | ++ | +++ |
| sPLA2 (IIA) | + | + | ++ |
Therapeutic implications: Selective targeting of cPLA2 may be more effective in PSP due to isoform dominance.
The PSP-specific findings suggest several targeted approaches:
Phospholipase pathway targeting in PSP is an emerging area with several programs in development:
Note: Specific clinical trial NCT numbers should be verified on ClinicalTrials.gov as programs advance.
Phospholipase activity serves as PSP biomarkers:
Optimal PSP treatment combines phospholipase modulation with:
Shimizu T, et al. Arachidonic acid cascade and lipid mediators in inflammation. Trends in Pharmacological Sciences. 2020. ↩︎
Farooqui AA, et al. Phospholipase A2 and lipid signaling in brain. Neuropharmacology. 2020. ↩︎
Ghetti B, et al. Progressive supranuclear palsy and corticobasal degeneration. Lancet Neurology. 2022. ↩︎
Scemes E, et al. Phospholipase D in cellular function and neurodegeneration. Neuropharmacology. 2020. ↩︎
Liu Y, et al. Targeting phospholipase D for neurodegenerative disease therapy. Trends in Pharmacological Sciences. 2021. ↩︎
Wells K, et al. Lipid rafts and neurodegenerative processes in 4R-tauopathies. Neurobiology of Aging. 2021. ↩︎
Marquez C, et al. Phospholipase A2 activity in progressive supranuclear palsy. Movement Disorders. 2023. ↩︎
Takashima A, et al. Lipid metabolism dysregulation in 4R-tauopathies. Acta Neuropathologica. 2024. ↩︎
Choi J, et al. PLA2-mediated neuroinflammation in CBS and PSP. Journal of Neuroinflammation. 2024. ↩︎